The U.S. Court of Appeals for the Federal Circuit sided with a jury’s 2017 finding that Teva swayed doctors away from using GlaxoSmithKline’s drug Coreg (carvedilol) for a use of its drug that was ...
After a ‘skinny label’ was used to market a generic version of a pricey brand-name medicine, more consumers gained access to the lower-cost copycat drug and saved on out-of-pockets cost, a new study ...
In its “skinny label” legal saga with Teva, GSK has hit back following the U.S. solicitor general’s call for the Supreme Court to rehear the years-long case. In a supplemental brief filed this week, ...
Positron Emission Tomography–Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study Generic competition can be delayed if ...
Paul Barker, Michele Bosch, Tom Irving, Kyu Yun Kim, Stacy Lewis, and Daniele San Román of Finnegan set out how Sanofi, Vanda and GSK can aid pharma counsel Strategically-minded in-house and private ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback